Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 1
2016 2
2019 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

4 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.
Campochiaro PA, Peters KG. Campochiaro PA, et al. Curr Diab Rep. 2016 Dec;16(12):126. doi: 10.1007/s11892-016-0816-5. Curr Diab Rep. 2016. PMID: 27778249 Review.
Tie2 is a tyrosine kinase receptor located predominantly on vascular endothelial cells that plays a central role in vascular stability. ...Angiopoietin-2 (Angpt2) and vascular endothelial-protein tyrosine ph
Tie2 is a tyrosine kinase receptor located predominantly on vascular endothelial cells that plays a centr
Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2.
Campochiaro PA, Sophie R, Tolentino M, Miller DM, Browning D, Boyer DS, Heier JS, Gambino L, Withers B, Brigell M, Peters K. Campochiaro PA, et al. Ophthalmology. 2015 Mar;122(3):545-54. doi: 10.1016/j.ophtha.2014.09.023. Epub 2014 Nov 12. Ophthalmology. 2015. PMID: 25439435 Clinical Trial.
PURPOSE: AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine phosphatase (VE-PTP) that promotes Tie2 activation and reduces vascular leakage and neovascularization in mouse mode …
PURPOSE: AKB-9778 is a small-molecule competitive inhibitor of vascular endothelial-protein tyrosine p
Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression.
Campochiaro PA, Khanani A, Singer M, Patel S, Boyer D, Dugel P, Kherani S, Withers B, Gambino L, Peters K, Brigell M; TIME-2 Study Group. Campochiaro PA, et al. Ophthalmology. 2016 Aug;123(8):1722-1730. doi: 10.1016/j.ophtha.2016.04.025. Epub 2016 May 26. Ophthalmology. 2016. PMID: 27236272 Clinical Trial.
PURPOSE: To assess the effect of AKB-9778 alone or in combination with ranibizumab in subjects with diabetic macular edema (DME). ...AKB-9778 was well tolerated, with no clear by-treatment differences in adverse events. CONCLUSIONS: Activation o …
PURPOSE: To assess the effect of AKB-9778 alone or in combination with ranibizumab in subjects with diabetic macular edema
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease.
Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Hussain RM, et al. Expert Opin Investig Drugs. 2019 Oct;28(10):861-869. doi: 10.1080/13543784.2019.1667333. Epub 2019 Sep 26. Expert Opin Investig Drugs. 2019. PMID: 31513439 Review.
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Activation of Tie-2 receptor via Ang-1 maintains vas
Introduction: The Tie-2/Angiopoietin pathway is a therapeutic target for the treatment of neovascular age-related macular dege …
Feedback